
Global law firm Hogan Lovells has announced the hiring of Jennifer Fleury, a prominent lawyer from the U.S. Federal Trade Commission (FTC), as part of its Washington, D.C. office. Fleury, who joins the firm as a partner, brings substantial expertise in antitrust enforcement, a hot-button issue amid increasing regulatory scrutiny of mergers and acquisitions in the United States.
Fleury previously served as deputy chief trial counsel in the FTC’s Bureau of Competition. She was instrumental in several high-profile cases, including leading the FTC’s successful lawsuit to block the proposed merger between IQVIA, a healthcare data and analytics firm, and DeepIntent, a healthcare advertising company owned by Propel Media. The agency argued that the deal would stifle competition, increase prices, and negatively impact patients. According to a statement from Hogan Lovells, a federal judge in Manhattan ruled in favor of the FTC in December 2023, which led to both companies abandoning the merger.
Before joining the FTC in 2022, Fleury had a distinguished career at the U.S. Department of Justice and also worked as a senior associate at Hogan Lovells. In her new role, she is expected to bolster the firm’s antitrust practice, particularly as the FTC continues to pursue aggressive enforcement under the leadership of Chair Lina Khan.
Per a statement by Fleury, antitrust enforcement will remain a focal point regardless of future political leadership. She emphasized that the FTC’s recently finalized merger-filing requirements would have long-term impacts beyond the Biden administration, signaling continued vigilance in monitoring corporate consolidation.
Under President Joe Biden, the FTC has ramped up its antitrust efforts. According to a 2022 Reuters analysis, the Biden administration challenged more mergers in its first two years than both the Obama and Trump administrations. This increased scrutiny comes as part of a broader effort to limit market consolidation and promote competition across industries.
With Fleury’s return, Hogan Lovells appears well-positioned to navigate the complex and evolving antitrust landscape, particularly as companies face heightened regulatory challenges.
Source: Hogan Lovells
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas